Source: https://topics.vlex.com/tags/amgen-v-chugai-500916
Timestamp: 2019-04-26 16:29:57+00:00

Document:
927 F.2d 1200 (Fed. Cir. 1991), 90-1273, Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.
52 F.3d 1026 (Fed. Cir. 1995), 93-1166, Ortho Pharmaceutical Corp. v. Genetics Institute, Inc.
Patent law's functionality malfunction and the problem of overbroad, functional software patents.
742 F.3d 998 (Fed. Cir. 2014), 2012-1660, Solvay S.A. v. Honeywell Int'l Inc.
52 F.3d 1043 (Fed. Cir. 1995), 94-1026, Glaxo Inc. v. Novopharm Ltd.
98 F.3d 1328 (Fed. Cir. 1996), 95-1247, Amgen, Inc. v. Genetics Institute, Inc.
299 F.3d 1313 (Fed. Cir. 2002), 01-1372, Teleflex, Inc. v. Ficosa North America Corp.
120 F.3d 1253 (Fed. Cir. 1997), 95-1322, Critikon, Inc. v. Becton Dickinson Vascular Access, Inc.
430 F.3d 1377 (Fed. Cir. 2005), 05-1009, IPXL Holdings, L.L.C. v. Amazon.com, Inc.
311 F.3d 1116 (Fed. Cir. 2002), 01-1417, Verve, LLC v. Crane Cams, Inc.
601 F.3d 1297 (Fed. Cir. 2010), 2009-1258, Vanderbilt University v. ICOS Corp.
314 F.3d 1313 (Fed. Cir. 2003), 01-1191, Amgen Inc. v. Hoechst Marion Roussel, Inc.
222 F.3d 1347 (Fed. Cir. 2000), 99-1251, Schering Corp v Amgen Inc.
Fencing Fisher: alternative methods for patenting expressed sequence tags.
40 F.3d 1223 (Fed. Cir. 1994), 93-1503, Burroughs Wellcome Co. v. Barr Laboratories, Inc.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.